Sort
15,440 grants matching “organoids”
Investigating the contribution of cellular senescence to the efficacy of radiation therapy.
$255,045Paul Bernard Romesser · Sloan-Kettering Inst Can Research · K08 · FY2024 · CA
Investigating the contribution of cellular senescence to the efficacy of radiation therapy.
$255,045Paul Bernard Romesser · Sloan-Kettering Inst Can Research · K08 · FY2023 · CA
Core C- Physiology
$255,010Nicholas Constantine Zachos · Johns Hopkins University · P30 · FY2019 · DK
The gut microbiome, interactions with primed colon states, and effects on adenoma formation and progression
$255,000Neelendu Dey · Fred Hutchinson Cancer Center · U54 · FY2025 · CA
Functional modeling of race-specific features underlying phenotypic reprogramming in metastatic stem cells from colorectal cancer patients
$254,999Karuna Ganesh · Sloan-Kettering Inst Can Research · R37 · FY2024 · CA
Molecular Pathology Shared Resource
$254,760Hanina Hibshoosh · Columbia University Health Sciences · P30 · FY2022 · CA
Molecular Pathology Shared Resource
$254,760Hanina Hibshoosh · Columbia University Health Sciences · P30 · FY2021 · CA
Molecular Pathology Shared Resource
$254,760Hanina Hibshoosh · Columbia University Health Sciences · P30 · FY2023 · CA
Molecular Pathology Shared Resource
$254,760Hanina Hibshoosh · Columbia University Health Sciences · P30 · FY2024 · CA
Molecular Pathology Shared Resource
$254,760Hanina Hibshoosh · Columbia University Health Sciences · P30 · FY2020 · CA
Hedgehog signaling in taste cell maintenance and regeneration
$254,627Philip A Beachy · Stanford University · R21 · FY2015 · NS
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
$254,405Joshua (chuck) Harrell · Virginia Commonwealth University · U54 · FY2024 · CA
Regulation of C. difficile infection by the cytokine interleukin-22 (IL-22)
$254,377Lauren A Zenewicz · University Of Oklahoma Hlth Sciences Ctr · P20 · FY2024 · GM
MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL
$254,250Roberta Zappasodi · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Core C- Physiology
$254,044Nicholas Constantine Zachos · Johns Hopkins University · P30 · FY2018 · DK
Core B: Human Tissue and Genomics Core
$253,810Shehzad Z. Sheikh · Univ Of North Carolina Chapel Hill · P01 · FY2021 · DK
Effect of Shiga toxin, OMVs, and innate immune cells on epithelial integrity of human colonoids during EHEC infection
$253,707John M Leong · Tufts University Boston · R21 · FY2021 · AI
Core B: Administrative and Data Management Core
$253,574Michael M. Shen · Columbia University Health Sciences · P01 · FY2023 · CA
Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer
$253,516Ravi Kumar Anchoori · Up Therapeutics, Inc. · R41 · FY2021 · CA
Resolving the relationship between mitochondrial dysfunction and the impact of non-syndromic autism spectrum disorder-related risk genes on neuronal structure and function
$253,500Laszlo Tamas Kozicz · Icahn School Of Medicine At Mount Sinai · R21 · FY2025 · HD
Bat pluripotent stem cells as a novel experimental system
$253,500Thomas P. Zwaka · Icahn School Of Medicine At Mount Sinai · R21 · FY2023 · AI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
$253,500Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Longitudinal single cell responses in human islet organoids to beta cell regenerative drugs
$253,500Esra Karakose-Balioglu · Icahn School Of Medicine At Mount Sinai · R03 · FY2025 · DK
Core B: Biospecimen Core
$253,465Ryan C Fields · Washington University · P50 · FY2024 · CA
Targeting molecular vulnerabilities of ovarian cancer
$253,377Sarah James Hill · Dana-Farber Cancer Inst · K08 · FY2020 · CA